PI3K/Akt/mTOR-IN-2 |
| Catalog No.GC66463 |
PI3K/Akt/mTOR-IN-2 est un inhibiteur de la voie PI3K/AKT/mTOR. PI3K/Akt/mTOR-IN-2 possèdent des effets anticancéreux et une sélectivité contre les cellules MDA-MB-231 avec une valeur IC50 de 2,29 μM. PI3K/Akt/mTOR-IN-2 peut induire l'arrêt du cycle cellulaire cancéreux et l'apoptose.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2757804-89-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].
PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1].
Cell Proliferation Assay
| Cell Line: | PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1] |
| Concentration: | 0.5 - 100 μM |
| Incubation Time: | 72 hours |
| Result: | Exhibited effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM. |
Cell Cycle Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 24 hours |
| Result: | Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1. |
Apoptosis Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 24, 48 and 72 hours |
| Result: | Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners. |
Western Blot Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 48 hours |
| Result: | Increased the expression of Bax, and decreased the expression of Bcl-2 |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *